Abstract
The objective of this 2-year, double-blind, placebo-controlled, randomized trial involving 48 participants was to determine if biweekly miconazole powder prevents onychomycosis recurrence. Intent-to-treat analysis found no significant differences in mycologic, clinical, or complete onychomycosis reinfection rates or time to reinfection. Limitations include small sample size and dosing regimen.
Original language | English (US) |
---|---|
Pages (from-to) | 717-720 |
Number of pages | 4 |
Journal | Journal of the American Academy of Dermatology |
Volume | 53 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2005 |
Externally published | Yes |
Bibliographical note
Funding Information:Funding source: Coloplast Corp, Skin Health Division, through a generous, unrestricted research grant. Dr Warshaw's career has been supported by a VA Cooperative Studies Clinical Research Career Development Grant.